Posaconazole
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Fungal Infection
Conditions
Fungal Infection
Trial Timeline
Nov 1, 2008 → Mar 1, 2010
NCT ID
NCT00811642About Posaconazole
Posaconazole is a phase 3 stage product being developed by Merck for Fungal Infection. The current trial status is completed. This product is registered under clinical trial identifier NCT00811642. Target conditions include Fungal Infection.
What happened to similar drugs?
9 of 20 similar drugs in Fungal Infection were approved
Approved (9) Terminated (4) Active (9)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (11)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00686621 | Pre-clinical | Completed |
| NCT05065658 | Pre-clinical | Completed |
| NCT03318159 | Phase 2 | Completed |
| NCT03336502 | Phase 1 | Completed |
| NCT02387983 | Phase 1 | Completed |
| NCT02020213 | Approved | Withdrawn |
| NCT00811642 | Phase 3 | Completed |
| NCT00686543 | Approved | Completed |
| NCT00550732 | Phase 2 | Completed |
| NCT00726609 | Pre-clinical | Completed |
| NCT00034658 | Phase 3 | Completed |
Competing Products
20 competing products in Fungal Infection